Work

Tirzepatide-Associated Colonic Ischemia

Year: 2024

Type: article

Abstract: The use of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist tirzepatide has markedly increased for the treatment of weight loss and management of diabetes mellitus. Gastrointestinal adverse effects of GLP-1/GIP agonist therapy, including nausea, vomiting, and constipation, are common. We report a case of colonic ischemia in a 62-year-old woman which developed in association with the use of tirzepatide for weight loss. This report highlights a potential risk relationship between GLP-1/GIP agonist therapy and colonic ischemia and identifies risk factors that should be considered before prescribing tirzepatide.

Source: ACG Case Reports Journal

DOI: 10.14309/crj.0000000000001551

Authors: David Bayless, Jasraj Singh, Byoung Uk Park, Seth Sweetser

Institution: Mayo Clinic

Language: English

Topic: Abdominal vascular conditions and treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

Funder: National Heart, Lung, and Blood Institute